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ABSTRACT
Objectives: The observation that pathogenic bacteria
are commonly tolerated in the human nose, yet drive
florid inflammation in the lung, is poorly understood,
partly due to limited availability of primary human cells
from each location. We compared responses to
bacterial virulence factors in primary human nasal and
alveolar cells, and characterised the distribution of Toll-
interacting protein (TOLLIP; an inhibitor of Toll-like
receptor (TLR) signalling) in the human respiratory
tract.
Methods: Primary cells were isolated from nasal
brushings and lung tissue taken from patients
undergoing pulmonary resection. Cells were exposed
to lipopolysaccharide, lipoteichoic acid, peptidoglycan,
CpG-C DNA or tumour necrosis factor (TNF). Cytokines
were measured in cell supernatants. TOLLIP was
characterised using quantitative real-time PCR and
immunofluorescence.
Results: In primary alveolar, but not primary nasal,
cells peptidoglycan significantly increased secretion of
interleukin (IL)-1β, IL-6, IL-8, IL-10 and TNF. TLR2
expression was significantly higher in alveolar cells and
correlated with IL-8 production. TOLLIP expression
was significantly greater in nasal cells.
Conclusion: In conclusion, primary human alveolar
epithelial cells are significantly more responsive to
peptidoglycan than primary nasal epithelial cells. This
may partly be explained by differential TLR2
expression. TOLLIP is expressed widely in the human
respiratory tract, and may contribute to the regulation
of inflammatory responses.
INTRODUCTION
Hospital-acquired infections (HAIs) are
common and associated with signiﬁcant mor-
bidity and mortality.1 Pneumonia is associated
with the highest mortality among the HAIs.1 2
The pathogenesis of hospital-acquired pneu-
monia is thought to involve recurrent micro-
aspiration of mircoorganisms which have
asymptomatically colonised the patient’s
oropharynx/nasopharynx during the course
of hospital admission.2
Why the nasal epithelium should tolerate
these microorganisms well, while the alveolar
epithelium mounts such a ﬂorid inﬂamma-
tory response, remains poorly understood. A
better understanding of this paradox has
been hampered by difﬁculties in accessing
primary cells from the human nose and
alveoli.
We therefore sought to characterise the
effects of key virulence factors from
Staphylococcus aureus and Pseudomonas aerugi-
nosa (recognised as key pathogens in nosoco-
mial pneumonia)2 on human primary nasal
and alveolar epithelial cells. An additional
aim was to determine whether
Toll-interacting protein (TOLLIP, an
endogenous inhibitor of Toll-like receptor
(TLR) signalling)3 4 was expressed in the
human respiratory tract and, if so, whether
there was differential expression in nasal and
alveolar epithelium. This protein has been
implicated as a key regulator of inﬂammatory
responses in the large intestine, contributing
to the dampening of TLR responses to
microbe-associated molecular patterns
derived from the extensive community of
commensal organisms.5 6 However, remark-
ably little is known about TOLLIP expression
in the human respiratory tract.
The primary hypothesis for this study was
that primary alveolar cells would mount a
KEY MESSAGES
▸ Peptidoglycan exerts a significant proinflamma-
tory cytokine response in primary human alveo-
lar epithelium but not in primary human nasal
epithelium.
▸ The Toll-like receptor regulator Toll-interacting
protein is widely expressed in the human
respiratory tract.
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brisk response to inﬂammatory stimuli, associated with
minimal or absent TOLLIP expression, whereas primary
nasal cells would exhibit a blunted response to inﬂam-
matory stimuli, associated with abundant TOLLIP
expression.
METHODS
Derivation of cells
Primary human nasal epithelial cells, bronchial epithe-
lial cells and type II alveolar epithelial cells were
obtained from patients undergoing elective pneumonec-
tomy or lobectomy for cancer. Methods for obtaining
and culturing the nasal and alveolar cells have been
described elsewhere.7 8 Bronchial epithelial cells were
obtained using a cytology brush passed through an
endotracheal tube during the surgical procedure. Cells
were seeded onto plates coated with type I rat tail colla-
gen (Sigma-Aldrich, St Louis, Missouri, USA) and
allowed to achieve conﬂuence. Cells were studied at
passage 2. Informed written consent was provided by all
participants providing primary cells.
The human colonic carcinoma cell line T84 and the
human nasal carcinoma cell line RPMI 2650 were from
LGC Promochem (Manassas, Virginia, USA; ATCC
numbers CCL-248 and CCL-30 respectively). A549 cells
(derived from a human alveolar cell carcinoma) were
available in-house.
Cell stimulation experiments
Conﬂuent cells were treated with 100 ng/mL of ultra-
pure lipopolysaccharide (LPS) derived from P. aeruginosa
strain PA01 (a gift from Professor Ian Poxton, University
of Edinburgh), 10 μg/mL of S. aureus peptidoglycan
(PGN; Fluka, Sigma-Aldrich), 10 μg/mL of S. aureus lipo-
teichoic acid (LTA; Sigma-Aldrich), 10 ng/mL of recom-
binant human tumour necrosis factor (TNF; R&D
Systems, Minneapolis, USA), 1 μΜ CpG-C DNA (ODN
2395; HyCult Biotechnology b.v., Uden, the
Netherlands) or medium alone (all ﬁnal concentra-
tions). Cells were incubated for 24 h at 37°C and super-
natants were removed and stored at −80°C until
estimation of interleukin (IL)-1β, IL-6, IL-8, IL-10,
IL-12p70 and TNF assayed using the BD Cytometric
Bead Array (CBA) Human Inﬂammatory Cytokine kit
(BD Biosciences), with analysis performed using a BD
FACSArray Bioanalyzer System.
RNA extraction, reverse transcriptase PCR and real-time
quantitative PCR
Total RNA was extracted using the total RNA isolation
kit Nucleospin RNAII (Macherey-Nagel, Duren,
Germany). 1 μg RNA was reverse transcribed using the
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Carlsbard, California, USA). Primers and
probes are summarised in a table in the online supple-
mentary section.
A Taqman Low Density Array (TLDA; Applied
Biosystems) was used to assess the stability of potential
housekeeping genes. Based on the normalisation score,
Cyclophilin A (PPIA) had the lowest variability rate in the
samples assayed. Results were normalised using a
TaqMan endogenous control (Applied Biosystems).
Diluted cDNA (1:100) was used as a template for the
PCR reaction and samples were loaded onto the Applied
Biosystems 7900HT Fast Real-Time PCR System. The spe-
ciﬁcity of the reactions was controlled using ‘no tem-
plate’ and ‘no reverse transcription’ controls. Results
were normalised to the human PPIA gene using the
standard curve method. Standard curves for the genes
of interest were prepared using the plasmids
pcDNA3-TLR9-YFP, Addgene plasmid 13642,
pcDNA3-TLR4-YFP, Addgene plasmid 13018 and
pUC19/human IL-8 Addgene plasmid 17610. Pooled
DNA was used in the standard curves for PPIA, TOLLIP
and TLR2.
Immunocytochemistry and confocal microscopy
Conﬂuent cells were detached using trypsin/EDTA solu-
tion (10 min at 37°C), and centrifuged. Resuspended
cells were seeded onto glass coverslips for 15 min and
incubated overnight at 37°C. Medium was replaced with
ice-cold methanol for 10 min, the cells were washed and
then blocking was performed using 2% goat serum for
30 min. Cells were dried and antibodies were applied
overnight as appropriate: murine monoclonal IgG1
against human cytokeratin 18, murine monoclonal
IgG2a against human cytokeratin 19, murine monoclo-
nal IgG2a against human TLR2 (all Invitrogen), poly-
clonal rabbit antihuman TLR4 IgG and polyclonal
rabbit antihuman TOLLIP IgG (Abcam). Controls com-
prised murine isotype monoclonal antibodies
(Invitrogen) or, where polyclonal primaries were used,
non-immune rabbit IgG (Invitrogen). The following day
cells were washed with phosphate buffered saline and
secondary antibodies applied for 1 h. Secondary anti-
bodies comprised AlexaFluor488-conjugated goat anti-
mouse IgG (Invitrogen) or goat antirabbit IgG
conjugated to AlexaFluor 488 (Invitrogen) as appropri-
ate. Cells were washed, dried and Vectashield with DAPI
(Vector Laboratories, Burlingame, California, USA)
added. Cells were visualised using a Leica TCS SP5 con-
focal microscope (Leica Microsystems CMS GmbH,
Mannheim, Germany), and photomicrographs taken.
Coculture of cell lines with S. aureus
The cell lines RPMI 2650 or A549 were seeded at a
density of 1×106 cells per well. On the same day 5 mL of
Modiﬁed Eagles Medium (MEM; Sigma-Aldrich) was
inoculated with S. aureus strain Newman, and incubated
overnight at 37°C with continuous shaking. The follow-
ing day an aliquot was inoculated in 5 mL of MEM and
allowed to reach logarithmic phase. Bacteria were
washed and resuspended in MEM to achieve an optical
density of approximately 0.1. Known volumes were (A)
2 Moncayo-Nieto OL, Wilkinson TS, Brittan M, et al. BMJ Open Resp Res 2014;1:e000046. doi:10.1136/bmjresp-2014-000046
Open Access
 group.bmj.com on September 17, 2014 - Published by bmjopenrespres.bmj.comDownloaded from 
added directly to cells and (B) plated onto tryptic soy
agar, so that viable bacterial concentrations could be
determined by quantifying colony forming units (CFU)
the next day. After infection, cells were incubated for a
further 4 h at 37°C prior to cell lysis and RNA extraction
as above.
Statistics
Friedman’s test was used to provide a global indication
of whether any signiﬁcant difference existed across the
conditions applied to cultured cells. Post hoc analysis
comparing unstimulated and stimulated cells was per-
formed using Dunn’s test. Comparisons of numerical
data between groups were carried out using the
Mann-Whitney U test. Comparison of proportions
between groups was carried out using Fisher’s exact test.
Correlations were analysed using Spearman’s test. All
statistical analyses were performed using GraphPad
Prism software (GraphPad Software, La Jolla, California,
USA). Statistical signiﬁcance was considered to be at the
p<0.05 level.
RESULTS
Primary nasal cells were successfully cultured from 6
patients, and primary alveolar cells from 7 (in two cases
nasal and alveolar cell were cultured from the same
patient). The two groups of patients were similar in
their baseline characteristics, although there were more
women in the group providing alveolar cells (results
from the patients providing nasal cells appear ﬁrst in
all the following comparisons: median age 65 vs
60 years; smoking history100% vs 71%; women 50% vs
86%; mean forced expiratory volume in 1 s 85% vs 84%
of predicted; mean diffusing capacity for carbon mon-
oxide (Tco) 63% vs 75% of predicted; no signiﬁcant
difference for any of the comparisons). The patients
were admitted for resection of non-small cell lung
cancer, with the exception of two patients admitted for
resection of solitary metastases. Characterisation by
quantitative reverse transcriptase PCR (qRT-PCR)
demonstrated that cultured nasal epithelial cells consist-
ently expressed the epithelial cell markers cytokeratin
18 and 19 and alveolar epithelial cells expressed the
type II pneumocyte markers SP-C and AQP-3 (data not
shown, methods described in the online supplementary
section).
A range of bacterial virulence factors was applied to
primary cells and the cytokine responses were examined
by CBA and qRT-PCR. All of the cytokines examined
could be produced by primary nasal epithelial cells.
However, none of the measured cytokines were signiﬁ-
cantly upregulated by exposure to PGN, LTA, LPS or
CpG (table 1). In contrast, exposure to TNF induced a
signiﬁcant upregulation of IL-8 and IL-6 secretion (but
not the other cytokines studied).
Alveolar cell responses were assessed in parallel with
nasal cells. LPS and LTA failed to signiﬁcantly alter
secretion of any of the cytokines (table 2). However, in
contrast to the nasal cells, exposure to PGN signiﬁcantly
increased production of all cytokines studied in alveolar
cells from every patient studied, with the exception of
IL-12, suggesting a differential TLR2 response in
primary human alveolar versus nasal epithelial cells.
Similarly to the response of primary nasal cells,
TNF-mediated stimulation induced signiﬁcant elevations
in secretion of IL-6, IL-8 and IL-10 from alveolar cells,
suggesting no major differences in signalling down-
stream of the TNF receptor between these two cell
types.
Given the differential secretion of IL-8 in response to
PGN, the effect of this bacterial TLR agonist on IL-8
mRNA production was also analysed. No signiﬁcant
increase in IL-8 expression was observed in either cell
type (data not shown), suggesting that at least some of
the effect of PGN on IL-8 secretion in alveolar cells may
be post-transcriptional.
Given that PGN mediates its effects largely through
TLR2-mediated recognition and signalling, expression
of TLR2 in primary nasal and alveolar epithelial cells
was also assessed by qRT-PCR (ﬁgure 1A). TLR2 expres-
sion was signiﬁcantly greater in alveolar epithelial cells
than in nasal cells (p=0.0043). In contrast, no signiﬁcant
differences in expression of TLR4 and TLR9 were
observed between these two cell types (data not shown).
Interestingly, TLR2 expression correlated signiﬁcantly
with IL-8 secretion in nasal and epithelial cells, both
under basal (p=0.0144) and PGN-stimulated (p=0.0074)
conditions (ﬁgure 1B).
In addition to differential expression of TLR2, the
expression of the TLR regulator TOLLIP was evaluated.
TOLLIP expression has been clearly deﬁned in the T84
colonic carcinoma cell line6; therefore, we initially char-
acterised our novel TOLLIP qRT-PCR assay in this
setting. A band of the expected size was consistently
detected, and was absent in negative controls
(ﬁgure 2A). TOLLIP expression was quantiﬁed in cul-
tured primary nasal and type II alveolar epithelial cells
(from n=5 and n=6, respectively) treated under identical
conditions. Basal TOLLIP mRNA expression was
observed in nasal and alveolar cells but was found to be
signiﬁcantly higher (p<0.05) in the primary nasal epi-
thelial cells (ﬁgure 2B).
Owing to the difﬁculties in obtaining sufﬁcient
numbers of primary cells, and the difﬁculties inherent
in applying live bacteria to cells, the effect of S. aureus
on TOLLIP expression was studied in cell lines. Clear evi-
dence for basal TOLLIP expression was observed in
nasal and alveolar cell lines, and 4 h exposure to
S. aureus did not appear to inﬂuence this (ﬁgure 2C, D),
suggesting a non-inducible expression in these cell
types.
Primary nasal and bronchial epithelial cells demon-
strated a broadly similar pattern of TOLLIP protein
expression, with diffuse punctate staining throughout the
cytoplasm, and a suggestion (in a proportion of cells) of
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peripheral accentuation of staining around the cell mem-
brane (ﬁgure 3A–D). Punctate staining was also visible in
type II alveolar epithelial cells (ﬁgure 3E, F).
DISCUSSION
To our knowledge, this study is among the ﬁrst to
compare the differential response of primary human
nasal and alveolar epithelial cells to a range of identical
inﬂammatory stimuli, and the ﬁrst to systematically
describe TOLLIP expression and localisation in the
human respiratory tract.
The ﬁndings suggest that primary nasal epithelial cells
have a relatively limited repertoire of responsiveness to
inﬂammatory stimuli, generating a statistically signiﬁcant
(but still numerically modest) increase in the proinﬂam-
matory cytokines IL-6 and IL-8, only in response to
stimulation with TNF, but not TLR agonists. This respon-
siveness to TNF is consistent with ﬁndings elsewhere.7
Other studies have suggested that primary human nasal
epithelial cells have a relatively restricted nasal cytokine
responsiveness to stimulation, broadly in keeping with
ﬁndings here.9 10 However, unlike our results, both
these studies found responsiveness of IL-8 to a variety of
Table 1 Constitutive and stimulated cytokine production by primary nasal epithelial cells
Stimulant
Basal
Staphylococcus aureus
PGN
S. aureus
LTA
Pseudomonas aeruginosa
LPS CpG TNF
IL-1β (pg/mL) 7.1
0–18.7
7.7
0–23.8
4.2
0–21.9
3.6
0–16.4
6
0–17.3
8.1
0–165
IL-6 (pg/mL) 29.7
13.7–313
140
21.6–695
52.1
6.3–459
139
7.9–279
45
4.7–535
956 **
67.5–3173
IL-8 (pg/mL) 504
192–1557
1363
378–3821
663
297–2309
740
131–4295
520
11.8–2531
7817 ***
2033–48 688
IL-10 (pg/mL) 9.2
4–18.7
12.5
4–21.6
7.1
0–14.5
6.4
0–18.6
6.5
0–21.1
13
0–67
IL-12 (pg/mL) 13.2
3.6–19.8
12.1
0–21
8.8
0–16.1
10.3
0–21.4
10.4
0–26.7
10.4
0–23.3
TNF (pg/mL) 10
1.7–15
6.2
2–24.3
7.2
0–11.8
6.5
3–16.1
6.3
0–17.5
†
Data are expressed as median (upper line, italic) and range (lower line, normal text). n=6 for all conditions. PGN and LTA were applied at
10 μg/mL, LPS at 100 ng/mL, CpG at 1 μM and TNF at 10 ng/mL. Statistical analysis was by Friedman’s test and Dunn’s post hoc test.
*p<0.05, **p<0.01, ***p<0.001 relative to basal levels, by Dunn’s post hoc test.
†TNF was used as a positive control; TNF was not measured in TNF-stimulated cells.
IL, interleukin; LPS, lipopolysaccharide; LTA, lipoteichoic acid; TNF, tumour necrosis factor; PGN, peptidoglycan.
Table 2 Constitutive and stimulated cytokine production by primary type II alveolar epithelial cells
Stimulant
Basal
Staphylococcus
aureus
PGN S. aureus LTA
Pseudomonas
aeruginosa
LPS CpG TNF
IL-1β (pg/mL) 5
2.5–8
17.2 **
5–152
3.4
1.6–12.5
6.3
2.2–14
7.5
1.7–11
11
1.2–85.3
IL-6 (pg/mL) 236
8.3–1276
927 *
121–9060
333
7.6–716
214
8.2–533
228
12.6–803
1205 **
34.1–4029
IL-8 (pg/mL) 2273
707–11 226
7444 *
1283–100 000
2002
843–21 914
1507
649–13 548
2919
636–40 775
31 721 ***
9450–78 198
IL-10 (pg/mL) 15
2.6–1276
25.4 **
3.5–5000
23.2
3.6–716
19.2
3–504
20.2
0–803
26 *
3.5–4029
IL-12 (pg/mL) 8
5.4–19.7
7.3
6.6–31.2
8.3
4.9–30
12.7
3.5–25
12.0
2.7–28.6
7
2.7–30.3
TNF (pg/mL) 10
3.6–21.2
29 *
6.5–279
5
0–21.4
12
2.3–26.7
7.0
0–15.7
†
Data are expressed as median (upper line, italic) and range (lower line, normal text). n=7 for all conditions. PGN and LTA were applied at
10 μg/mL, LPS at 100 ng/mL, CpG at 1 μM and TNF at 10 ng/mL. Statistical analysis was by Friedman’s test and Dunn’s post hoc test.
*p<0.05, **p<0.01, ***p<0.001 relative to basal levels, by Dunn’s post hoc test.
†TNF was used as a positive control; TNF was not measured in TNF-stimulated cells.
IL, interleukin; LPS, lipopolysaccharide; LTA, lipoteichoic acid; TNF, tumour necrosis factor; PGN, peptidoglycan.
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stimuli, while a further study found that both IL-6 and
IL-8 were increased in response to LPS.11
In contrast to the relative quiescence of primary nasal
cells, we found that primary alveolar epithelial cells were
characterised by a more ﬂorid response to PGN and
TNF that spanned a wider range of cytokines. These
observations appear consistent with the hypothesis that
bacterial virulence factors are better tolerated by the
nose. Our data suggest that S. aureus PGN induces a par-
ticularly ﬂorid inﬂammatory response in alveolar epithe-
lial cells. It may be particularly relevant that, in our
hands, the levels of expression of TLR2 (which recog-
nises PGN) correlated closely with responsiveness, as
assessed by IL-8 secretion. The implication seems to be
not only that alveolar epithelium expresses more ‘target’
for PGN, but that PGN can upregulate TLR2 expression
more effectively on alveolar epithelium. This may go
some way to explaining the differential responsiveness of
nasal and alveolar epithelium, and perhaps why the lung
mounts such a striking inﬂammatory response to S.
aureus, a common ‘coloniser’ of the human nose.12 It is
far less clear why PGN produced a proinﬂammatory
response in our alveolar epithelial cells while LTA and
LPS did not. In the case of LPS, the lack of responsive-
ness could not be attributed to an absence of appropri-
ate receptors, as TLR4 is well described on alveolar
epithelial cells, and other groups have described LPS
responsiveness in alveolar epithelium.13 14 The appar-
ently selective and ﬂorid response of alveolar cells to
PGN in our hands is intriguing. It is tempting to specu-
late that membrane-based TLR regulators may recognise
different virulence factors preferentially, and/or that
PGN effects intracellular TLR regulators in a different
way from other virulence factors in primary alveolar epi-
thelial cells. However, this must remain purely specula-
tive until further data are available.
To investigate further potential reasons for differential
innate immune responsiveness between the nose and
lung, we drew on data describing an excess of TOLLIP in
the large intestine, where bacterial tolerance is essential.
We believe this to be the ﬁrst systematic characterisation
of TOLLIP’s presence and location in primary cells from
the human respiratory tract. TOLLIP has been cloned
from a human lung cDNA library,15 and expression has
been described in pooled human lung tissue,16 but the
purpose of those studies did not include cellular localisa-
tion. TOLLIP mRNA and TOLLIP protein have been
detected in commercially available human small airway
epithelial cells.17 TOLLIP mRNA has also been described
in pleural effusions.18 Our ﬁndings in ﬁgure 3 comple-
ment those in small airway epithelial cells by suggesting
that TOLLIP is produced throughout the length of the
Figure 1 TLR2 expression is significantly higher in alveolar epithelium than in nasal epithelium, and correlates with IL-8
secretion. (A) Comparison of TLR2 expression in primary nasal and alveolar epithelium, in the presence or absence of PGN.
*p<0.05, **p<0.01 using the Mann-Whitney U test. (B) Correlation between TLR2 expression and IL-8 secretion in primary cells,
in the presence or absence of PGN. Dots represent nasal epithelial cells, grey triangles represent alveolar cells. *p<0.05,
**p<0.01 using Spearman’s rank correlation coefficient. TLR, Toll-like receptor; IL, interleukin; PGN, peptidoglycan.
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human respiratory tract. These observations are at vari-
ance with our initial hypothesis. However, the ﬁnding of
higher TOLLIP mRNA expression in primary nasal epi-
thelial cells in comparison to type II alveolar epithelial
cells broadly supports the hypothesis. The observation
that TOLLIP is constitutively and ubiquitously expressed
in human respiratory epithelium is consistent with a
potential role as a key regulator of inﬂammatory
Figure 3 TOLLIP is found in
primary human nasal, bronchial
and alveolar epithelial cells.
Primary nasal (A and B),
bronchial (C and D) and type II
alveolar epithelial cells (E and F)
were fixed, blocked with 2% goat
serum and incubated with a rabbit
polyclonal antibody against
TOLLIP (A, C and E) or isotype
control (B, D and F). Nuclei were
stained with DAPI (blue).
Secondary antibody was
antirabbit IgG conjugated with
Alexa 488 (green). Images were
analysed using confocal
microscopy. Three nasal
samples, one bronchial and one
alveolar were analysed. Scale bar
equals 50 μm in A–D, and 10 μm
in E and F (TOLLIP,
Toll-interacting protein).
Figure 2 TOLLIP expression in
nasal and alveolar epithelium.
(A) T84 cells were plated at two
different cell densities: 5×105 per
well (lanes 1, 2); 2×106, (lanes 3,
4). Lane 5 represents a negative
control without the reverse
transcriptase. GAPDH was used
as a housekeeping gene.
(B) TOLLIP expression was
quantified in primary nasal and
alveolar epithelium. *p<0.05 by
Mann-Whitney U test. (C and D)
Cell lines were infected with
Staphylococcus aureus strain
Newman. RNA extraction was
performed followed by RT-PCR.
Panel C shows RPMI 2650 cells
—and panel D A549 cells—
infected with S. aureus. Lanes:
(1) positive control for TOLLIP
from cell line T84; (2 and 3)
unstimulated; (4 and 5) cells with
S. aureus at 1.1×105 cfu/mL;
(6 and 7) cells with S. aureus at
1.6×105 cfu/mL. GAPDH was
used as a housekeeping gene.
Band size for TOLLIP 347 bp and
for GAPDH 727 bp (TOLLIP,
Toll-interacting protein; RT-PCR,
reverse transcriptase PCR).
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responses.3 4 19 However, we must stress that we found no
evidence for differential TOLLIP responsiveness to bac-
terial virulence factors in nasal and alveolar cell lines.
TOLLIP binds to IL-1 receptor-associated kinase
(IRAK-1), preventing proinﬂammatory signalling. On
stimulation of cells with LPS or IL-1, a receptor complex
rapidly forms, incorporating TOLLIP bound to IRAK-1.
Sufﬁcient phosphorylation of IRAK-1 allows its dissoci-
ation from TOLLIP, and proinﬂammatory signalling (for
example, through nuclear factor κ B) rapidly ensues.
TOLLIP is therefore well placed to regulate inﬂamma-
tory processes. TOLLIP’s ready availability in organs
regularly exposed to bacteria, such as the gut, nose and
lung, seems potentially important in this regard.
Interestingly, TOLLIP has been implicated in LPS hypor-
esponsiveness in human monocytes and human primary
intestinal epithelial cells.20 21
The functional importance of TOLLIP as a regulator
of acute inﬂammation is supported by emerging clinical
data. For example, in the Chinese Han population,
increased susceptibility to sepsis is conferred by poly-
morphisms in the TOLLIP gene that result in reduced
TOLLIP function.22 Similarly, functional polymorphisms
in a Vietnamese population have been associated with
susceptibility to tuberculosis.23 In a Caucasian popula-
tion, TOLLIP gene polymorphisms have been weakly
associated with increased susceptibility to atopic derma-
titis.24 Observational data suggest that TOLLIP expres-
sion is reduced in tissue from coeliac disease and
necrotising enterocolitis.25 26
While the data here are some way from having direct
clinical relevance, validation of a ﬂorid alveolar response
to PGN in other cohorts might yield avenues for further
exploration. In particular, selective administration of
anti-TLR2 or speciﬁc TLR regulators early in the ﬂorid
proinﬂammatory phase of staphylococcal pneumonia
seems theoretically attractive in a condition with contin-
ued high mortality despite modern antibiotics and sup-
portive care. The association between TLR2 expression
and IL-8 secretion in unstimulated and PGN-stimulated
cells is potentially relevant in this regard.
Comparison of responses in primary human cells
increases the relevance of this study. However, we recog-
nise that there are several potential limitations. First, all
of our patients had cancer and most had a long history
of smoking, which is known to affect cytokine secretion
by epithelial cells throughout the respiratory tract.27 28
We cannot exclude the possibility that smoking or sys-
temic effects of patients’ illness may have altered cyto-
kine production or cellular responsiveness. Second,
numbers of patients were small, reﬂecting low availability
and technical issues in obtaining cells. While recognis-
ing this limitation, we felt that studying primary human
cells would be by far the most relevant way to advance
this area. Furthermore, consistent effects in studies of
this nature help to generate hypotheses for further
investigation. Third, as in any model system, we obvi-
ously cannot be certain that isolated, cultured epithelial
cells behave as they would in their complex native envir-
onment. Finally, while epithelial cells are numerically
dominant in the nose and alveoli, we cannot exclude
the possibility that our stimuli might induce effects in
other, less well-represented cells in these regions.
Furthermore, in rodents it has been suggested that type
I alveolar epithelial cells (notoriously hard to isolate
from humans) respond more ﬂoridly to inﬂammatory
stimuli than do type II cells.29
In summary, primary human alveolar epithelial cells
appear to mount a more exuberant inﬂammatory response
to PGN and TNF than do primary human nasal epithelial
cells. PGN’s effects may relate to the relative abundance
and regulation of TLR2 in the upper and lower airway.
TOLLIP is produced throughout the human respiratory
tract. TOLLIP is expressed in greater levels in nasal cells
than in alveolar epithelial cells, but differential TOLLIP
expression in nasal and lung cells in response to bacterial
virulence factors was not observed. These data suggest that
relative expression of TLR2 and TOLLIP might play a role
in the tolerant nature of the nasal epithelium to bacteria.
Further studies are required to address a range of remain-
ing questions—these include, but are by no means limited
to: whether other TLR regulators are differentially
expressed (constitutively or inducibly) in nasal versus alveo-
lar epithelium; whether bacterial virulence factors differen-
tially inﬂuence TLR regulator expression within alveolar
epithelial cells (favouring a proinﬂammatory effect of PGN
but not the other virulence factors measured here) and
whether PGN can evade membrane-based TLR regulators
on alveolar cells.
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